The chromatin regulator WDR5 is a regulator of translation, and small molecule inhibitors or degraders of WDR5 can be used to treat triple-negative breast cancer.

MLL4 (KMT2D) is a major mammalian H3K4 mono- and di-methyltransferase that is essential for enhancer activation, cell-type-specific gene expression, and cell differentiation.

Epigenetic regulator MLL3 is mutated and lost in human hepatocellular carcinoma due to its ability to activate a well-defined tumor suppressor and cell death in transformed cells.

Arginine methylation regulates mRNA translation of key protooncogenes via an RGG/RG motif-containing protein called Aven.

The H3K4 methyltransferase Setd1b is intrinsically required for hematopoietic stem and progenitor cell homeostasis and regulates lineage specification in mice.

ctDNA predict prognosis and treatment response of mTNBC patients more sensitively than traditional tumor markers, which implies ctDNA may be valuable for individualized treatment decision-making and paves the way for a non-invasive real-time clinical management strategy in patients with mTNBC.

Systematic assessment of de novo variants in patients with sporadic inborn errors of immunity led to the identification of promising candidate variants in known and novel immune genes, supporting its implementation in the routine diagnostic evaluation of these patients.

The iPSCs derived from OA cartilage showed memory of disease which affect its chondrogenic potential and regulation at epigenetic and metabolic level may be used to control the regenerative potential of these iPSCs.

As the first to track clonal evolution from precancerous to metastatic lesions in gallbladder cancer patients, spatial and temporal analyses reveal how subclonal diversity in precancerous stage changes toward the metastasis, which help early detection and effective treatment of cancer.

The HOXA9 reporter and genetic screens facilitated the functional interrogation of the HOXA9 regulome and advanced our understanding of the molecular regulation network in HOXA9-driven leukemia.